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Abstract. Background: Transient receptor potential vanilloid
type 1 (TRPV1) has been studied in human malignancies, but
has not been studied in epithelial ovarian cancer (EOC). We,
therefore, investigated the significance of TRPV1 and
correlation with phosphatase and tension homolog (PTEN) in
EOC. Materials and Methods: Immunohistochemical analyses
for TRPV1 and PTEN were performed using a tissue
microarray. Moreover, the role of TRPV1 in cell growth was
assessed in a EOC cell line. Results: High TRPV1 expression
and the combination of high TRPV1 and low PTEN expression
were an independent prognostic factor for overall survival and
disease-free survival. In vitro results demonstrated that
knockdown of TRPV1 was associated with decreased cell
viability and colony formation. Conclusion: There is a strong
association between TRPV1 and PTEN and the combination
of TRPV1 and PTEN is a strong indicator of prognostic
predictor in EOC.
Epithelial ovarian cancer (EOC) is the second most common
gynecological malignancy in women, with a 1.3%
prevalence, and one of the top leading causes of cancer-
related deaths in the United States of America (1). Women
with EOC experience a high mortality rate because it is
usually diagnosed in advanced stages. Even with a greatly
improved treatment strategy, the 5-year overall survival rate
remains about 30% (2). Therefore, there is a great need for
research studies that focus on uncovering the molecular
pathogenesis of EOC and exploring more specific and
effective prognostic markers to improve patient outcomes.
Ca2+ is one of the important second messengers linking
activation of membrane receptor and downstream signaling
cascade, and Ca2+ homeostasis controls various physiological
and cellular processes such as tumorigenesis. Therefore,
abnormal expression of Ca2+ channels has been studied in
various cancers, and interest in the role of transient receptor
potential (TRP) channels, a type of Ca2+ permeable
nonselective cation channel, is also emerging. Transient
receptor potential vanilloid type 1 (TRPV1), which belongs
to the TRP channel family of proteins, was originally
regarded as a critical sensor in response to mechanical,
thermal, and chemical stimuli, since it is predominantly
found in afferent neurons. It has been suggested that TRPV1
is associated with cell proliferation, differentiation, and
invasion characteristics of cancer (3, 4). Previous studies
have reported that TRPV1 acts as a tumor suppressor by
inducing apoptosis and preventing tumor progression upon
activation by its agonist in melanomas (5). However, other
studies reported that TRPV1 deficiency prohibited cell
proliferation in prostate cancer and sensitized stress-induced
apoptosis in colorectal cancer, indicating an oncogenic role
(6, 7). In accordance with previous studies, it can be
suspected that the role of TRPV1 is tumor type-specific, and
the mechanisms underlying the regulation of cancer cell
growth by TRPV1 remain to be evaluated. Moreover, the
role of TRPV1 in EOC has not been yet clarified. 
Thus, in this study, we aimed to evaluate the molecular
and functional significance of TRPV1 expression in EOC.
Our results indicated that TRPV1 was overexpressed in EOC
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and associated with poor prognosis. Furthermore, in vitro
functional studies showed that inhibition of TRPV1
suppressed the development of EOC cells.
Materials and Methods
Patients and tumor samples. Tissue samples from 217 EOCs, 57
borderline and 153 benign ovarian tumors, and 79 non-adjacent
normal epithelia were included in the study. Tumor tissues were
gathered from patients who underwent debulking surgery at the
Gangnam Severance Hospital between 1996 and 2012 and from the
Korea Gynecologic Cancer Bank as part of the Bio & Medical
Technology Development Program of the Ministry of the National
Research Foundation (NRF) funded by the Korean government
(MIST) (NRF-2017M3A9B8069610). The International Federation
of Gynecology and Obstetrics (FIGO) classification was used for
tumor staging. Clinical information, including survival time,
survival status, age, and surgical procedure, were collected by
reviewing medical records. The therapeutic response was evaluated
with Response Evaluation Criteria in Solid Tumors (RECIST;
version 1.0) by computed tomography (8). The cell type and tumor
grade were obtained by reviewing the pathological reports. All
tumor tissues were histologically examined by a gynecologic
pathologist, and all biological samples were obtained after informed
consent from the participants, according to the guidelines of the
institutional review board (IRB) of Gangnam Severance Hospital.
Tissue microarray construction and immunohistochemistry. Tissue
microarray (TMA) with one-millimeter cores was constructed from
archival formalin-fixed paraffin-embedded (FFPE) tissue blocks.
The samples were arrayed into a recipient paraffin block with a
manual tissue arrayer MTA–1 (Beecher Instruments Inc., Silver
Spring, MD, USA). For immunohistochemical staining, the TMA
blocks were cut into serial 5-μm thick sections, deparaffinized with
xylene, and rehydrated gradually from ethanol to distilled water.
Endogenous peroxidase activity was blocked in 3% hydrogen
peroxide (H2O2) for 10 min. The sections were immersed in an
antigen retrieval buffer at pH 9 (Dako, Carpinteria, CA, USA) and
heated for 20 min in a steam pressure cooker (Pascal, Dako) to
retrieve antigenicity. The sections were treated with a protein block
(Dako) for 20 min to block non-specific staining. The sections were
then incubated with anti-TRPV1 antibody (Alomone, Jerusalem,
Israel; Rabbit polyclonal antibody, Cat# ACC-030, 1:1,000 for 1 h)
and anti-PTEN antibody (Cell Signaling, Danvers, MA; Rabbit
monoclonal antibody, Clone 9559L, 1:100 for 1 h) in Dako
Autostainer Plus (Dako) for 1 h. For antigen-antibody reaction,
sections were incubated with Dako EnVision+ Dual Link system-
HRP (Dako) for 30 min and visualized with 3,3’-diaminobenzidine
(DAB; Dako). Tissue sections were counterstained lightly with
hematoxylin and examined with light microscopy. Appropriate
negative controls were simultaneously prepared. 
Evaluation of immunohistochemistry staining. After IHC staining, all
glass slides were scanned digitally by a high-resolution optical
scanner Nanozoomer 2.0 HT (Hamamatsu Photonics K.K., Japan).
The digital imaging analysis (DIA) software used was the Visiopharm
Integrator System v6.5.0.2303 (VIS; Visiopharm, Hørsholm,
Denmark). After training the system with digital “painting” examples
of the nucleus in the image, an algorithm for nucleus-specific signal
selection was designed manually. The cytoplasm was defined by
outlining the defined nucleus. TRPV1 and PTEN were scored based
on staining intensity of brown-colored diaminobenzidine (DAB)
(0=negative, 1=weak, 2=moderate, and 3=strong). The overall
immunostaining score was calculated by multiplying the staining
intensity by percentage of positive cells (possible range, 0-300).
Cell culture. The human ovarian cancer cell line, A2780, was
purchased from The European Collection of Cell cultures (ECACC,
Salisbury, UK), and human embryonic kidney 293 (HEK293) cell
from Systemic Biosciences (SBI, Palo Alto, CA, USA). A2780 cells
were cultured at Roswell Park Memorial Institute (RPMI) in
medium containing 10% FBS, 1% penicillin, and 1% streptomycin.
The HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 1% penicillin and 1% streptomycin.
A2780 cells and HEK293 cells were cultured at 37˚C in a
humidified atmosphere containing 5% CO2.
Transfection and generation of stable cell lines. For the generation of
sh-TRPV1 stable cell lines, pLKO.1 TRPV1 shRNA libraries were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Of the lentivirus
constructs tested, two with the best efficiency were used for the
experiments here, using the human TRPV1 sequence CCGGCCGT
TTCATGTTTGTCTACATCTCGAGATGTAGACAAACATGAAACG
GTTTT for shRNA#1 and CCGGGAAGTTTATCTGCGACAG
TTTCTCGAGAAACTGTCGCAGATAAACTTCTTTTTG for
shRNA#2. The non-targeted shRNA control vector (pLKO.1) was
purchased from Sigma-Aldrich. Lentiviral production was done by co-
transfecting pLKO.1 and packaging vectors into HEK293 cells by using
Lipofectamine™ 2000 (Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. At 48 and 72 h post-
transfection, virus particles were collected. A2780 cells were
transduced, and cells with positive transduction were selected by
puromycin (2 μg/ml).
Protein extraction and western blot. Total cell lysates were isolated
by using cell lysis buffer [50 mM Tris pH 7.4, 150 mM NaCl, 0.5%
Triton X-100, 1 mM ethylendiaminetetraacetic acid (EDTA)]
containing proteinase inhibitor cocktail (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). The lysates were centrifuged at 13,500
rpm for 30 min, and protein concentrations were determined by
bicinchoninic acid (BCA) assay (Sigma-Aldrich). A total of 40 μg
proteins were separated by 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto 0.2-µm nitrocellulose membranes (Pall Corporation, Port
Washington, NY, USA). The membranes were blocked with 5%
nonfat dry milk in TBST mixture (50 mM Tris, 150 mM NaCl,
0.1% Tween-20, pH 7.5) for 1 h at room temperature, washed with
TBST, and subsequently incubated with primary antibodies anti-
TRPV1 (Invitrogen, Carlsbad, CA, USA - Rabbit polyclonal
antibody, Cat# PA1-748) and α-tubulin (Santa Cruz Biotechnology,
Cat# sc-5286). Primary antibodies against each protein were
detected by using secondary antibodies conjugated with horseradish
peroxidase. Signals were detected by chemiluminescence using the
ImmunoCruz luminol reagent (Santa Cruz Biotechnology) and
quantified using ImageJ analysis software (US National Institutes
of Health, Bethesda, MD, USA). 
Cell proliferation assay. Cell proliferation was measured with the
EZ-CYTOX reagent (DoGenBio, Seoul, Republic of Korea, Cat#
EZ-3000). In brief, cells were seeded at 1×104 cells/well onto a 96
well plate with a final volume of 100 μl/well. Cells were incubated
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at 37˚C for 60 min after adding 10 μl of EZ-CYTOX reagent per
well and then incubated on an orbital shaker for 1 min. The
absorbance value at optical density (OD) 450 nm was subsequently
measured with a microplate reader (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) and recorded at day 0, 1, 2, and 4. The
experiment was performed in triplicates. 
Colony formation assay. In order to examine clonogenicity, the cells
were seeded in a 6 well plate at 500 cells/well. The cells were
cultured in RPMI-1640 supplemented with 10% FBS and 1%
penicillin/streptomycin for 2 weeks. The cells were fixed with 100%
methanol for 10 min and stained with 0.5% crystal violet for 30
min, followed by washing with distilled water. Stained cells were
dissolved in 2% dimethyl sulfoxide (DMSO) for 20 min on an
orbital shaker. The absorbance value was measured at 595 nm on a
microplate reader (Bio-Rad Laboratories, Inc.). Each experiment
was repeated three times. 
Cell counting assay. Cells were seeded at 2.5×105 cells/well in a 6-
well plate and incubated for 7 days. The cells were washed with
phosphate-buffered saline and treated with trypsin-
ethylenediaminetetraacetic acid. After detachment using trypsin, the
cells were diluted with 1 ml of fresh medium and transferred to the
dedicated LUNA™ Cell Counting Slides (Logos Biosystems,
Gyeonggi-do, Republic of Korea, Cat #L12001). Cell counting was
performed with the LUNA-II™ (Logos Biosystems) automated cell
counter in disposable counting chambers. Each experiment was
performed three times. 
Statistical analysis. Statistical analyses of TRPV1 and PTEN
were performed using the Mann-Whitney test or the Kruskal-
Wallis test where appropriate. Kaplan-Meier methods and log-
rank test were used to evaluate the overall survival (OS) and
disease-free survival (DFS) curve. The Cox proportional hazard
model was performed for both univariate and multivariate models
to estimate hazard ratios (HRs) and confidence intervals (CIs).
Statistical analyses were performed using SPSS version 25.0
(SPSS Inc., Chicago, IL, USA). A value of p<0.05 was
considered statistically significant.
Results
TRPV1 and PTEN protein expression in EOC. To investigate
the clinical role of TRPV1 and PTEN in EOC, we assessed
TRPV1 and PTEN expression by immunohistochemistry
(IHC) using TMAs of 217 EOC tissues, 57 borderline
tumors, 153 benign tumors, and 79 nonadjacent normal
epithelial tissues. However, only 204 EOC tissues, 50
borderline tumors, 118 benign tumors, and 37 nonadjacent
normal epithelial tissues for TRPV1 and 202 EOC tissues,
50 borderline tumors, 95 benign tumors, and 79 nonadjacent
normal epithelial tissues for PTEN were interpretable for
IHC analysis due to complexity and staining of samples.
Representative IHC images for TRPV1 and PTEN in EOC
are shown in Figure 1A. As observed in Figure 1A and Table
I, expression level of TRPV1 was higher compared to
borderline tumors, benign tumors, and nonadjacent normal
epithelial tissues (all p<0.001). We further evaluated the
clinicopathological characteristics of TRPV1 in which high
expression of TRPV1 (TRPV1+) was significantly associated
with advanced FIGO stage (p<0.001; Table I and Figure 1B),
serous cell type (p<0.001), and positive CA125 (p=0.035;
Table I). In terms of PTEN, there were no significant
differences in clinicopathological characteristics between
EOC and other groups (Table I). 
Correlation between TRPV1 and PTEN expression. Since
both TRPV1 and PTEN have been reported to be related to
the PI3K/AKT pathway and Ca2+ homeostasis, Spearman’s
rank correlation analysis was performed to determine the
association between the two proteins. The results showed a
negative correlation trend between TRPV1 and PTEN in
EOCs (Spearman’s rho=−0.103, p=0.144; Figure 2A), but
interestingly, significant negative correlation in stage III/IV
was observed when performing subgroup analysis according
to stage (Spearman’s rho=−0.241, p=0.006; Figure 2B). 
In addition, the combined high expression of TRPV1 and
loss of PTEN expression (TRPV1+/PTEN–) was associated
with advanced FIGO stage (p=0.013; Figure 2C) and serous
cell type (p=0.009; Figure 2D). Other clinicopathological
parameters were not found to be associated with
TRPV1+/PTEN– expression in EOCs.
Prognostic significance of TRPV1 and PTEN expression.
We further evaluated the prognostic significance of TRPV1
and PTEN in EOCs, in which TPRV1+ patients had
significantly worse OS compared to those with low
TRPV1– (p<0.001; Figure 3A). In addition, DFS showed
the same result as the OS (p<0.001; Figure 3B). Compared
to TRPV1, high PTEN expression (PTEN+) showed
significantly better DFS than low PTEN expression
(PTEN–) (p<0.001; Figure 3D).
Moreover, OS and DFS were identified between
TRPV1+/PTEN– and TRPV1–/PTEN+ expression groups
with the Kaplan-Meier plot. Significant differences were
observed in OS and DFS (both p<0.001; Figure 3E and
Figure 3F). Furthermore, OS and DFS were compared with
Cox proportional univariate and multivariate analyses (Table
II). Multivariate analysis revealed that TRPV1+ expression
strongly served as an independent prognostic factor for both
OS and DFS (HR=4.19, 95% CI=1.34-12.18, p=0.009;
HR=8.22, 95% CI=3.37-20.04, p<0.001). The combined
marker, TRPV1+/PTEN–, was related to poor DFS
(HR=2.25, 95% CI=1.06-4.74, p=0.003) and in particular,
TRPV+/PTEN– was a significantly strong prognostic
biomarker for OS (HR=4.17, 95% CI=2.36-7.38, p<0.001).
Moreover, FIGO stage and cell type were good parameters
for predicting OS (p=0.046, p<0.001), and other parameters,
including FIGO stage (p<0.001), cell type (p=0.024) and
tumor grade (p=0.010), were independent poor prognostic
factors for DFS.  
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Figure 1. TRPV1 and PTEN expression in formalin-embedded non-adjacent normal epithelium, benign tumor, borderline tumor, and epithelial
ovarian cancer tissues. (A) Representative immunohistochemical images of TRPV1 and PTEN in non-adjacent normal epithelium, benign tumor,
borderline tumor, and epithelial ovarian cancer tissues. Scale bar: 60 μm. (B) IHC staining score for TRPV1 and PTEN in nonadjacent normal
epithelium, benign tumor, borderline tumor, and epithelial ovarian cancer tissues.
Knockdown of TRPV1 in EOC cells. As the biological role of
TRPV1 in EOC is not fully investigated, we studied its
potential roles in EOC cell lines by modulating intracellular
TRPV1 expression with short- hairpin TRPV1 RNAi in a
A2890 (sh-TRPV1 #1, #2) cell line. The relative expression
level of TRPV1 was measured with western blot, and upon
confirmation of knockdown (Figure 4A), we analyzed the
effect of TRPV1 with two different assays to investigate the
short- and long-term proliferative ability. When TRPV1 was
knocked-down in A2890 cells, cell growth was significantly
decreased compared to the shRNA-control group (Figure 4B).
Next, we performed cell counting and colony formation assays
to assess the role of TRPV1 in tumorigenesis and found that
number of cells and colony formation in sh-TRPV1 were
significantly decreased compared to the shRNA-control (Figure
4C and D). Taken together, these results demonstrated that
blocking TRPV1 expression inhibited cell growth in EOC cells.
Discussion 
As EOC patients experience high rates of relapse and
mortality, it is necessary to investigate the potential
molecular biomarkers that can be of prognostic and
predictive value for EOC. Therefore, in this study, we first
identified the expression of TRPV1 and examined the impact
on EOC progression and then studied the association of
TRPV1 with PTEN and the potential combined effect of
TRPV1 and PTEN as a prognostic marker for EOC. 
First, we examined TRPV1 expression and explored its
clinical significance with IHC analysis using EOCs,
borderline tumors, benign tumors, and nonadjacent normal
epithelia. The results revealed that TRPV1 expression was
markedly increased in EOC tissues compared to borderline
tumors, benign tumors, and nonadjacent normal epithelium
(all p<0.001). Furthermore, TRPV1 expression increased in
advanced FIGO stage and CA125-positive patients (p<0.001
and p<0.035, respectively). Notably, TRPV1+ status was an
independent prognostic factor for both OS and DFS. In the
same context, the expression of TRPV1 was studied in breast
and prostate cancers and, as in our study, its expression was
higher in cancer tissues than in normal tissues and was
associated with poor prognosis (9-11). However, other
studies on hepatocellular carcinoma, transitional cell
carcinoma of bladder, and renal cell cancer have reported
that expression of TRPV1 was inversely correlated with
cancer progression (12-14). The main reason for this
inconsistency would be that the hormones can modify
transcription regulation, localization at the plasma membrane
surface, and intrinsic activity of TRPV1 (15). Morelli et al.
(6) evaluated androgen receptor (AR) and TRPV1 co-
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Table I. Expression of TRPV1 and PTEN in relation to clinicopathological characteristics in immunohistochemical analysis.
                                                        No.                                                        TRPV1                              No.                                                  PTEN          
                                                                              Mean score (95% CI)                 p-Value                                   Mean score (95% CI)               p-Value
All study subjects                          409                  132.1 (127.9-136.3)                                               426                 90.5 (86.2-94.8)                          
Diagnostic category                                                                                                                                                                                                           
  Normal                                           37                   100.0 (89.7-110.4)                    <0.001                   79                95.9 (89.5-102.4)                     0.614
  Benign                                         118                  109.3 (103.6-115.0)                                                 95                 87.2 (80.0-94.5)                          
  Borderline                                      50                  118.3 (110.5-126.1)                                                 50                88.0 (74.6-101.4)                         
  Cancer                                          204                  154.5 (148.6-160.4)                                               202                 90.6 (83.3-97.9)                          
FIGO stage                                                                                                                  0.001                                                                                          0.559
  I-II                                                  55                  138.8 (127.4-150.3)                                                 55                92.2 (77.5-107.2)                         
  III-IV                                           130                  161.7 (154.2-169.2)                                               128                 87.2 (78.2-96.3)                          
Cell type                                                                                                                    <0.001                                                                                        0.514
  Serous                                          137                  166.6 (159.6-173.5)                                               136                 88.9 (80.4-97.4)                          
  Others                                            67                  129.8 (121.3-138.4)                                                 66                94.1 (79.7-108.4)                         
Tumor grade                                                                                                               0.673                                                                                          0.612
  Well/Moderate                               86                  155.2 (146.0-164.3)                                                 86                 88.1 (77.0-99.3)                          
  Poor                                             102                  157.8 (149.4-166.2)                                               102                92.0 (81.6-102.4)                         
CA125                                                                                                                         0.035                                                                                          0.636
  Negative                                        33                  139.9 (126.7-153.1)                                                 33                93.8 (76.8-110.8)                         
  Positive                                        167                  157.2 (150.5-163.9)                                               165                 89.0 (80.8-97.3)                          
Chemosensitivity                                                                                                        0.710                                                                                          0.536
  Sensitive                                      171                  156.5 (150.1-163.0)                                               170                92.2 (84.0-100.4)                         
  Resistant                                        17                  160.5 (144.1-176.8)                                                 16                83.5 (57.8-109.3)                         
FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval. Protein expression was evaluated by immunohistochemical
analysis using tissue arrays, as described in Materials and Methods.
expression through mRNA and protein levels in advanced
prostate cancer tissues, and found that expression levels of
AR and TRPV1 were markedly elevated in these tissues
compared to those in benign prostate hyperplasia. More
importantly, they showed a strong correlation between AR
and TRPV1 expression levels. Moreover, a strong down-
regulation in AR and TRPV1 mRNA levels was observed in
a patient who received androgen deprivation therapy
compared to those who did not receive androgen deprivation
therapy, suggesting that TRPV1 might be modulated by
androgen. In this study, we did not show a correlation
between TRPV1 and estrogen. The ovary, however, is a
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Figure 2. Spearman’s rank correlation analysis between TRPV1 and PTEN expression. TRPV1 expression showed a trend of negative correlation
with PTEN level in EOCs (A), while in stage III/IV, there was a significant negative correlation between TRPV1 and PTEN (B). TRPV1–/PTEN+
was significantly associated with FIGO stage (C) and serous cell type (D). 
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Table II. Univariate and multivariate analyses of the associations between prognostic variables and overall and disease-free survival in epithelial
ovarian cancer.
                                                  Overall survival hazard ratio (95% CI), p-Value                     Disease-free survival hazard ratio (95% CI), p-Value
                                                      Univariate                                  Multivariate                                 Univariate                                 Multivariate 
FIGO stage (III-IV)          4.68 (1.85-11.79), 0.001              2.66 (1.01-6.99), 0.046            5.88 (3.04-11.34), <0.001           4.06 (1.97-8.38), <0.001
Cell type (serous)              4.71 (1.87-11.87), 0.001              2.01 (0.75-5.40), 0.163             3.13 (1.86-5.29), <0.001             2.00 (1.09-3.65), 0.024
Tumor grade (poor)           1.69 (0.95-3.01), 0.073                               NA                              1.96 (1.29-2.99), 0.002               1.76 (1.14-2.70), 0.010
CA125+ (>35 U/ml)          2.10 (0.75-5.86), 0.153                               NA                              2.32 (1.17-4.62), 0.016               1.25 (0.56-2.76), 0.582
Age (>50)                           2.19 (1.21-3.96), 0.010               1.52 (0.83-2.78), 0.166              1.55 (1.04-2.31), 0.029               1.29 (0.84-1.98), 0.233
TRPV1+a                          7.18 (2.57-20.01), <0.001            4.18 (1.43-12.18), 0.009           7.47 (3.75-14.87), <0.001          8.22 (3.37-20.04), <0.001
PTEN–b                              1.96 (0.77-4.95), 0.152                               NA                              1.96 (1.07-3.58), 0.029               1.83 (0.96-3.48), 0.066
TRPV1+/PTEN–               3.95 (1.97-7.91), <0.001              2.25 (1.06-4.74), 0.033             4.42 (2.74-7.12), <0.001            4.17 (2.36-7.38), <0.001
CI, Confidence interval; NA, not applicable; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; NA, not applicable.
acut-off value of TRPV1+ is 125 over IHC score; bcut-off of PTEN+ is 138 over IHC score. 
Figure 3. Kaplan–Meier survival curves for TRPV1 and PTEN expression in EOC. EOC patients with high TRPV1 expression had a shorter overall
survival (A) (p<0.001) and worse 5-year disease-free survival (B) (p<0.001) than those with low TRPV1 expression. The patients with high
expression of PTEN showed a longer 5-year disease-free survival (D) (p=0.026) and those with high TRPV1/low PTEN had a shorter overall
survival (E) (p=0.021) and worse 5-year disease-free survival (F) (p<0.001) than patients with low TRPV1/high PTEN expression. 
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Figure 4. Effect of TRPV1 overexpression on EOC cells. Relative mRNA levels in control and TRPV1-knockdown A2780 cells (A). Viability curves
for A2780 cells transfected with sh-control, sh-TRPV1 knockdown (B). A2780 cells were collected at various time points. The viability of TRPV1
knockdown cells was decreased. Quantification of cell counting assay for sh-control and sh-TRPV1-transfected A2980 cells (C). It showed
significantly decreased cell number in sh-TRPV1 transfected A2980 cells compared to sh-control. The colony formation assay of sh-control and sh-
TRPV1 transfected A2980 cells (D) Left panel: Representative images of colonogenic assay; Right panel: Quantitative results of colonogenic assay.
Colony formation ability was decreased for the TRPV1 knockdown cells as compared with the control cells. The number of asterisks (*) indicates
the level of significance: *p≤0.05. Data and error bars represent the mean±SD of triplicate experiments.
hormone-affected reproductive organ, and synergetic
expression of TRPV1 by estrogen has been reported in
endometriosis patients (16). Therefore, accumulation of
estrogen may have some influence on TRPV1 expression,
and elevated expression of TRPV1 may promote expression
of other Ca2+-sensitive transcriptional regulators (17, 18). 
Another important finding of this study is that expression
of TRPV1 was significantly higher in serous-type EOC than
in others. The fourth edition of WHO classification placed
ovarian cancer into two different categories, type I and type
II, according to molecular profile, precursor lesion, way of
spread, and response to chemotherapy (19). Type 1 EOC
includes low-grade serous ovarian carcinoma (LGOSC),
mucinous, clear cell, malignant Brenner and endometrioid
tumors that generally show Ras and/or Raf mutation with
indolent and slow growth. Type II EOC, which exhibits p53
mutations, includes high-grade serous ovarian carcinoma
(HGOSC) undifferentiated carcinomas, and malignant mixed
mesodermal tumors. Among the many types of EOC,
HGOSC accounts for nearly 90% and exhibits a more
aggressive behavior. Despite continued research, there has
been no significant improvement in 5-year OS over the past
30 years. Therefore, it is necessary to identify a potential
biomarker that correlates with prognosis in Type II EOC,
especially HGOSC, in the future (20). In our study, among
137 serous type EOC patients, 13.7% had LGOSC and 85.1%
had HGOSC (1.2%: grade unknown). Taken together, our
results suggest that TRPV1 might be a crucial predictor for
poor prognosis of HGOSC and possible therapeutic target. 
In accordance with our results showing an association
between TRPV1 and cancer in clinical specimens, we set out
to explore the potential role of TRPV1 in the development
of a malignant phenotype in EOC cells by modulating
intracellular TRPV1 expression in A2890 cells. We found
that TRPV1 knockdown significantly decreased the
proliferative and clonogenic abilities of EOC cells. Similar
to our results, accumulative evidence has demonstrated the
role of TRPV1 in tumorigenesis of various cancers. Sung et
al. (7) identified the oncogenic role of TRPV1 in colorectal
cancer after observing that tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) was activated and
induced cell apoptosis when TRPV1 expression was blocked
by an antagonist in colorectal cells. Moreover, in prostate
cancer cells, TRPV1 overexpression activated its oncogenic
role via regulated extracellular signal-regulated kinase (ERK)
signaling (6). However, in glioma, TRPV1 overexpression
leads to cell death by inducing endoplasmic reticulum stress
(3). de Jong et al. (21) found that activation of TRPV1 by
capsaicin regulated Ca2+/calpain and protein tyrosine
phosphatase 1B (PTP1B) and suppressed intestinal
tumorigenesis. Considering these inconsistent results from
previous studies, we suspect that TRPV1 can show varying
functions depending on cancer type. One factor that could
affect TRPV1 function is tumor microenvironment, since
cytokine and receptor interactions vary by tumor type and
tissue content and consequently affect the different cancer-
related pathways in tumor microenvironments (22).
In addition to TRPV1, we investigated the expression of
PTEN and its association with TRPV1 in EOC. A dual lipid-
protein phosphatase, PTEN acts primarily as a tumor
suppressor by dysregulating the PI3K/AKT/mTOR pathway
in a large proportion of human cancers such as prostate, brain,
breast, thyroid, endometrial, sarcoma, and cervical cancers
(23-26). In our study, the expression levels of PTEN did not
differ between normal and cancer tissues. However, Cox
analysis revealed that low expression of PTEN is an
independent predictive factor for prognosis. These results may
be explained by the fact that more than 70% of PTEN
alterations are related to gene deletions that were determined
to yield intact PTEN by IHC, and only 30% are related to lack
of PTEN expression according to the TCGA database (27).
Moreover, for HGOSC, PTEN IHC in TCGA data showed
loss of PTEN in only 52 (15%) out of the 316 EOCs (28). 
After looking at the expression and survival analyses of
TRPV1 and PTEN, we examined the relationship between
TRPV1 and PTEN in EOCs, which showed a significant
negative correlation in advanced stages (stage III/IV). In
addition, combination of TRPV1 and PTEN (TRPV1+/PTEN)
showed high hazard ratio in the Cox regression analyses,
indicating a strong prognostic predictive factor. As mentioned
above, the association between TRPV1 and PTEN can be
observed through the PI3K/AKT pathway, since PTEN acts as
a tumor suppressor by inhibiting cell proliferation and induces
apoptosis via dephosphorylation of phosphatidylinositol
(3,4,5)-triphosphates to phosphatidylinositol 4,5-bisphosphate
in the PI3K/AKT pathway. A previous study also revealed that
activation of TRPV1 may exert anti-apoptotic effects in
ischemic/reperfusion injury of the heart via the PI3K/AKT
pathway (29). In addition to this result, numerous studies have
reported on the association of TRPV1 and the PI3K/AKT
pathway such as in dorsal root ganglion neurons (30) and
human HepG2 cells (30, 31). Taken together, we propose that
TRPV1 and PTEN showed correlation in our EOC specimens
through the PI3K/AKT pathway. Even though there is no
previous study investigating the correlation between TRPV1
and PTEN expression in various cancers, the study by Liu et
al. (32) is of particular interest. They observed that
overexpression of TRPV4 in colon cancer was associated with
poor prognosis and revealed the negative regulation of PTEN
upon TRPV4 activation via the AKT/mammalian target of
rapamycin (mTOR) signaling pathway. Furthermore, they
suggested that dysregulation of Ca2+ homeostasis by TRPV4
regulated the localization of PTEN by conformational changes
in major vault proteins in colon cancer. However, further
studies are warranted to understand the exact mechanism
underlying the role of TRPV1 and PTEN in EOC. 
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In this study, the evaluation of TRPV1 and PTEN expression
level in EOCs were performed by IHC. Immunostaining
techniques, IHC is the most practical methods to assess
expression levels of proteins in histopathology. It is relatively
inexpensive and easy to perform, and IHC provides not only a
semiquantitative assessment but also defines cellular
localization of protein expression. However, the determined
TRPV1 and PTEN expression accurately by IHC can be
significantly affected by numerous factors, such as temperature,
fixation and method of antigen retrieval (33, 34). Therefore, to
reduce the variability in scoring result of IHC, recommendation
guidelines should be published.
In conclusion, we investigated TRPV1 and PTEN expression
using IHC in a large cohort of patients with EOC. High TRPV1
expression was associated with poor DFS and OS, and high
PTEN expression showed a favorable prognosis in DFS. Cox
regression analysis confirmed that both TRPV1 and PTEN
might be important prognostic indicators of EOC. This result is
significant because it suggests that TRPV1 or combination of
TRPV1 and PTEN is applicable to the personalized therapy
approach based on the constancy of tumors. 
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